| Literature DB >> 30415446 |
Efthimios Dardiotis1, Athina-Maria Aloizou2, Vasileios Siokas2, George P Patrinos3,4, Georgia Deretzi5, Panayiotis Mitsias6, Michael Aschner7, Aristidis Tsatsakis8.
Abstract
Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease that affects motor neurons and leads to death within 2 to 3 years after the first symptoms manifest. MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression in fundamental cellular processes and, post-transcriptionally, the translation levels of target mRNA transcripts. We searched PubMed for studies that examined miRNAs in ALS patients and attempted to group the results in order to find the strongest miRNA candidate for servings as an ALS biomarker. The studies on humans so far have been diverse, yielding considerably heterogeneous results, as they were performed on a wide variety of tissues and subjects. Among the miRNAs that were found consistently deregulated are miR-206, miR-133, miR-149, and miR-338-3p. Additively, the deregulation of some specific miRNAs seems to compose a miRNA expression profile that is specific for ALS. More research is required in order for the scientific community to reach a consensus.Entities:
Keywords: Amyotrophic lateral sclerosis; Biomarker; Epigenetics; MicroRNA; Neurodegeneration
Mesh:
Substances:
Year: 2018 PMID: 30415446 DOI: 10.1007/s12031-018-1204-1
Source DB: PubMed Journal: J Mol Neurosci ISSN: 0895-8696 Impact factor: 3.444